Last reviewed · How we verify
HS-10241
At a glance
| Generic name | HS-10241 |
|---|---|
| Also known as | Almonertinib, c-met inhibitor |
| Sponsor | Jiangsu Hansoh Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Pharmacokinetic Study of HS-10241 Tablets in Subjects with Hepatic Impairment and Normal Hepatic Function (PHASE1)
- A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy (PHASE3)
- Study of HS-10241 in Combination With Almonertinib in Patients With Locally Advanced or Metastatic NSCLC (PHASE1)
- A Phase I Trial of HS-10241 in Solid Tumors (PHASE1)
- PhaseⅠStudy of the HS-10241 in Patients With Advanced Solid Tumors (PHASE1)
- Tolerability, Safety, Pharmacokinetics and Efficacy of HS-10241 Single Agent or Combined With Apatinib in Patients With Advanced Solid Tumors (PHASE1)
- A Trial of C-met Kinase Inhibitor HS-10241 in Subjects With Advanced Solid Tumours (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HS-10241 CI brief — competitive landscape report
- HS-10241 updates RSS · CI watch RSS
- Jiangsu Hansoh Pharmaceutical Co., Ltd. portfolio CI